Western blot analysis of alpha 1 Antichymotrypsin expression in human plasma lysate.
| A03948 | |
|
|
|
| ¥37,309.00 | |
|
|
|
|
|
|
| Ask us a question | |
| Specificity | This product is specific to alpha 1 Antichymotrypsin |
| Host Species | Rabbit |
| Immunogen | A synthesized peptide derived from human alpha 1 Antichymotrypsin |
| Species Reactivity | Human |
| Conjugate | Unconjugated |
| Working concentrations for specific applications should be determined by the investigators. The appropriate concentrations may be affected by secondary antibody affinity, antigen concentration, the sensitivity of the method of detection, temperature, the length of the incubations, and other factors. The suitability of this antibody for applications other than those listed below has not been determined. The following concentration ranges are recommended starting points for this product. | |||||||||||||
|
|||||||||||||
| Form | Liquid |
| Storage Buffer | Supplied in 10mM phosphate buffered saline , pH 7.4, 150mM sodium chloride, 0.05% BSA, 0.02% sodium azide and 50% glycerol. |
| Storage Instructions | Store at -20°C. This product is stable for 1 year upon receipt, when handled and stored as instructed. |
| Purification | Affinity-chromatography |
| Isotype | Rabbit IgG |
| Clonality | Monoclonal |
Western blot analysis of alpha 1 Antichymotrypsin expression in human plasma lysate.
| Target Background | Although its physiological function is unclear, it can inhibit neutrophil cathepsin G and mast cell chymase, both of which can convert angiotensin-1 to the active angiotensin-2. |
| Synonyms | SERPINA3; AACT; ACT; Antichymotrypsin; GIG24; GIG25; Serpin A3; SERPINA3; |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
